Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia

TUESDAY, June 13, 2023 -- Fixed-duration ibrutinib plus venetoclax is beneficial for patients with chronic lymphocytic leukemia, including those with high risk features, according to a study published online June 7 in Clinical Cancer Research.
John...